Effect of Cyclooxygenase-2 Inhibition on Renal Function After Renal Ablation

Kidney failure is the common end of hypertension and renal diseases. Several authors have suggested that vasodilatory prostaglandins participate in the hemodynamic mechanism responsible for the development of kidney failure. However, the mechanism by which prostaglandins are increased in renal disea...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hypertension (Dallas, Tex. 1979) Tex. 1979), 1999-10, Vol.34 (4, Part 2), p.848-853
Hauptverfasser: Sanchez, Pedro Lopez, Salgado, Luis Miguel, Ferreri, Nicholas R, Escalante, Bruno
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 853
container_issue 4, Part 2
container_start_page 848
container_title Hypertension (Dallas, Tex. 1979)
container_volume 34
creator Sanchez, Pedro Lopez
Salgado, Luis Miguel
Ferreri, Nicholas R
Escalante, Bruno
description Kidney failure is the common end of hypertension and renal diseases. Several authors have suggested that vasodilatory prostaglandins participate in the hemodynamic mechanism responsible for the development of kidney failure. However, the mechanism by which prostaglandins are increased in renal disease is not clear. Recently, 2 isoforms of the enzyme responsible for prostaglandin synthesis, cyclooxygenase, have been described as cyclooxygenase-1 (COX-1), a constitutive isoform, and cyclooxygenase-2 (COX-2), an inducible isoform. In the present study, we investigated whether COX-2-dependent prostaglandins participate in the evolution of renal functional changes after renal ablation. We inhibited prostaglandin synthesis by COX-1 and COX-2 with indomethacin (3 mg/kg) and prostaglandin synthesis by COX-2 with NS-398 (3 mg/kg) and tested the effect of these inhibitors on the renal functional changes elicited by renal ablation. Renal ablation produced an increase in urinary volume, protein, and prostaglandin E2, whereas urinary sodium and potassium were not affected and urinary osmolarity decreased; treatment with indomethacin or NS-398 partially prevented the renal functional changes elicited by renal ablation. Immunoblots for COX showed an increase in the expression of COX-2 protein 2 days after renal ablation. Furthermore, COX-2 mRNA expression was increased 1 day after renal ablation. These data suggest that COX-2-dependent prostaglandins participate in the renal mechanisms associated with the development of renal functional changes after renal ablation.
doi_str_mv 10.1161/01.hyp.34.4.848
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70853739</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70853739</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5426-716e45193be2f98b9a4ff4d10bebb40d7c93ef180a7f256e581e9760329b60f23</originalsourceid><addsrcrecordid>eNpdkNGLEzEQh4MoXj199k0WOXzbvUySzW4eS7nzDgqKKOhTSNKJ3TPd1GSXs_-9qS0ohpCQH99Mho-Q10AbAAnXFJrtYd9w0YimF_0TsoCWiVq0kj8lCwpK1Arg6wV5kfMDpSCE6J6TC6At47xjC7K-8R7dVEVfrQ4uxPjr8B1Hk7Fm1f24HewwDXGsyv5U4lDdzqP7kyz9hOkcLm0wx_AleeZNyPjqfF-SL7c3n1d39frD-_vVcl27VjBZdyBRtKC4ReZVb5UR3osNUIvWCrrpnOLooaem86yV2PaAqpOUM2Ul9YxfknenvvsUf86YJ70bssMQzIhxzrqjfcs7rgr49j_wIc6pjJw1KwpUmUEW6PoEuRRzTuj1Pg07kw4aqD5a1hT03bePmgstdLFcKt6c2852h5t_-JPWAlydAZOdCT6Z0Q35Lwe9ZOz4szhhjzEUm_lHmB8x6S2aMG01Lavo6mtQSkF5QF2OUvYbInySoA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>205291936</pqid></control><display><type>article</type><title>Effect of Cyclooxygenase-2 Inhibition on Renal Function After Renal Ablation</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Ovid Autoload</source><creator>Sanchez, Pedro Lopez ; Salgado, Luis Miguel ; Ferreri, Nicholas R ; Escalante, Bruno</creator><creatorcontrib>Sanchez, Pedro Lopez ; Salgado, Luis Miguel ; Ferreri, Nicholas R ; Escalante, Bruno</creatorcontrib><description>Kidney failure is the common end of hypertension and renal diseases. Several authors have suggested that vasodilatory prostaglandins participate in the hemodynamic mechanism responsible for the development of kidney failure. However, the mechanism by which prostaglandins are increased in renal disease is not clear. Recently, 2 isoforms of the enzyme responsible for prostaglandin synthesis, cyclooxygenase, have been described as cyclooxygenase-1 (COX-1), a constitutive isoform, and cyclooxygenase-2 (COX-2), an inducible isoform. In the present study, we investigated whether COX-2-dependent prostaglandins participate in the evolution of renal functional changes after renal ablation. We inhibited prostaglandin synthesis by COX-1 and COX-2 with indomethacin (3 mg/kg) and prostaglandin synthesis by COX-2 with NS-398 (3 mg/kg) and tested the effect of these inhibitors on the renal functional changes elicited by renal ablation. Renal ablation produced an increase in urinary volume, protein, and prostaglandin E2, whereas urinary sodium and potassium were not affected and urinary osmolarity decreased; treatment with indomethacin or NS-398 partially prevented the renal functional changes elicited by renal ablation. Immunoblots for COX showed an increase in the expression of COX-2 protein 2 days after renal ablation. Furthermore, COX-2 mRNA expression was increased 1 day after renal ablation. These data suggest that COX-2-dependent prostaglandins participate in the renal mechanisms associated with the development of renal functional changes after renal ablation.</description><identifier>ISSN: 0194-911X</identifier><identifier>EISSN: 1524-4563</identifier><identifier>DOI: 10.1161/01.hyp.34.4.848</identifier><identifier>PMID: 10523372</identifier><identifier>CODEN: HPRTDN</identifier><language>eng</language><publisher>Philadelphia, PA: American Heart Association, Inc</publisher><subject>Animals ; Biological and medical sciences ; Cyclooxygenase 1 ; Cyclooxygenase 2 ; Cyclooxygenase 2 Inhibitors ; Cyclooxygenase Inhibitors - pharmacology ; Cyclooxygenase Inhibitors - therapeutic use ; Dinoprostone - physiology ; Indomethacin - pharmacology ; Indomethacin - therapeutic use ; Isoenzymes - physiology ; Kidney Function Tests ; Male ; Medical sciences ; Membrane Proteins ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Nitrobenzenes - pharmacology ; Nitrobenzenes - therapeutic use ; Prostaglandin-Endoperoxide Synthases - physiology ; Rats ; Rats, Wistar ; Renal failure ; Renal Insufficiency - metabolism ; Renal Insufficiency - physiopathology ; Renal Insufficiency - prevention &amp; control ; Sulfonamides - pharmacology ; Sulfonamides - therapeutic use</subject><ispartof>Hypertension (Dallas, Tex. 1979), 1999-10, Vol.34 (4, Part 2), p.848-853</ispartof><rights>1999 American Heart Association, Inc.</rights><rights>2000 INIST-CNRS</rights><rights>Copyright American Heart Association, Inc. Oct 1999</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5426-716e45193be2f98b9a4ff4d10bebb40d7c93ef180a7f256e581e9760329b60f23</citedby><cites>FETCH-LOGICAL-c5426-716e45193be2f98b9a4ff4d10bebb40d7c93ef180a7f256e581e9760329b60f23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,3687,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1186226$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10523372$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sanchez, Pedro Lopez</creatorcontrib><creatorcontrib>Salgado, Luis Miguel</creatorcontrib><creatorcontrib>Ferreri, Nicholas R</creatorcontrib><creatorcontrib>Escalante, Bruno</creatorcontrib><title>Effect of Cyclooxygenase-2 Inhibition on Renal Function After Renal Ablation</title><title>Hypertension (Dallas, Tex. 1979)</title><addtitle>Hypertension</addtitle><description>Kidney failure is the common end of hypertension and renal diseases. Several authors have suggested that vasodilatory prostaglandins participate in the hemodynamic mechanism responsible for the development of kidney failure. However, the mechanism by which prostaglandins are increased in renal disease is not clear. Recently, 2 isoforms of the enzyme responsible for prostaglandin synthesis, cyclooxygenase, have been described as cyclooxygenase-1 (COX-1), a constitutive isoform, and cyclooxygenase-2 (COX-2), an inducible isoform. In the present study, we investigated whether COX-2-dependent prostaglandins participate in the evolution of renal functional changes after renal ablation. We inhibited prostaglandin synthesis by COX-1 and COX-2 with indomethacin (3 mg/kg) and prostaglandin synthesis by COX-2 with NS-398 (3 mg/kg) and tested the effect of these inhibitors on the renal functional changes elicited by renal ablation. Renal ablation produced an increase in urinary volume, protein, and prostaglandin E2, whereas urinary sodium and potassium were not affected and urinary osmolarity decreased; treatment with indomethacin or NS-398 partially prevented the renal functional changes elicited by renal ablation. Immunoblots for COX showed an increase in the expression of COX-2 protein 2 days after renal ablation. Furthermore, COX-2 mRNA expression was increased 1 day after renal ablation. These data suggest that COX-2-dependent prostaglandins participate in the renal mechanisms associated with the development of renal functional changes after renal ablation.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Cyclooxygenase 1</subject><subject>Cyclooxygenase 2</subject><subject>Cyclooxygenase 2 Inhibitors</subject><subject>Cyclooxygenase Inhibitors - pharmacology</subject><subject>Cyclooxygenase Inhibitors - therapeutic use</subject><subject>Dinoprostone - physiology</subject><subject>Indomethacin - pharmacology</subject><subject>Indomethacin - therapeutic use</subject><subject>Isoenzymes - physiology</subject><subject>Kidney Function Tests</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Membrane Proteins</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>Nitrobenzenes - pharmacology</subject><subject>Nitrobenzenes - therapeutic use</subject><subject>Prostaglandin-Endoperoxide Synthases - physiology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Renal failure</subject><subject>Renal Insufficiency - metabolism</subject><subject>Renal Insufficiency - physiopathology</subject><subject>Renal Insufficiency - prevention &amp; control</subject><subject>Sulfonamides - pharmacology</subject><subject>Sulfonamides - therapeutic use</subject><issn>0194-911X</issn><issn>1524-4563</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkNGLEzEQh4MoXj199k0WOXzbvUySzW4eS7nzDgqKKOhTSNKJ3TPd1GSXs_-9qS0ohpCQH99Mho-Q10AbAAnXFJrtYd9w0YimF_0TsoCWiVq0kj8lCwpK1Arg6wV5kfMDpSCE6J6TC6At47xjC7K-8R7dVEVfrQ4uxPjr8B1Hk7Fm1f24HewwDXGsyv5U4lDdzqP7kyz9hOkcLm0wx_AleeZNyPjqfF-SL7c3n1d39frD-_vVcl27VjBZdyBRtKC4ReZVb5UR3osNUIvWCrrpnOLooaem86yV2PaAqpOUM2Ul9YxfknenvvsUf86YJ70bssMQzIhxzrqjfcs7rgr49j_wIc6pjJw1KwpUmUEW6PoEuRRzTuj1Pg07kw4aqD5a1hT03bePmgstdLFcKt6c2852h5t_-JPWAlydAZOdCT6Z0Q35Lwe9ZOz4szhhjzEUm_lHmB8x6S2aMG01Lavo6mtQSkF5QF2OUvYbInySoA</recordid><startdate>199910</startdate><enddate>199910</enddate><creator>Sanchez, Pedro Lopez</creator><creator>Salgado, Luis Miguel</creator><creator>Ferreri, Nicholas R</creator><creator>Escalante, Bruno</creator><general>American Heart Association, Inc</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>199910</creationdate><title>Effect of Cyclooxygenase-2 Inhibition on Renal Function After Renal Ablation</title><author>Sanchez, Pedro Lopez ; Salgado, Luis Miguel ; Ferreri, Nicholas R ; Escalante, Bruno</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5426-716e45193be2f98b9a4ff4d10bebb40d7c93ef180a7f256e581e9760329b60f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Cyclooxygenase 1</topic><topic>Cyclooxygenase 2</topic><topic>Cyclooxygenase 2 Inhibitors</topic><topic>Cyclooxygenase Inhibitors - pharmacology</topic><topic>Cyclooxygenase Inhibitors - therapeutic use</topic><topic>Dinoprostone - physiology</topic><topic>Indomethacin - pharmacology</topic><topic>Indomethacin - therapeutic use</topic><topic>Isoenzymes - physiology</topic><topic>Kidney Function Tests</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Membrane Proteins</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>Nitrobenzenes - pharmacology</topic><topic>Nitrobenzenes - therapeutic use</topic><topic>Prostaglandin-Endoperoxide Synthases - physiology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Renal failure</topic><topic>Renal Insufficiency - metabolism</topic><topic>Renal Insufficiency - physiopathology</topic><topic>Renal Insufficiency - prevention &amp; control</topic><topic>Sulfonamides - pharmacology</topic><topic>Sulfonamides - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sanchez, Pedro Lopez</creatorcontrib><creatorcontrib>Salgado, Luis Miguel</creatorcontrib><creatorcontrib>Ferreri, Nicholas R</creatorcontrib><creatorcontrib>Escalante, Bruno</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sanchez, Pedro Lopez</au><au>Salgado, Luis Miguel</au><au>Ferreri, Nicholas R</au><au>Escalante, Bruno</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Cyclooxygenase-2 Inhibition on Renal Function After Renal Ablation</atitle><jtitle>Hypertension (Dallas, Tex. 1979)</jtitle><addtitle>Hypertension</addtitle><date>1999-10</date><risdate>1999</risdate><volume>34</volume><issue>4, Part 2</issue><spage>848</spage><epage>853</epage><pages>848-853</pages><issn>0194-911X</issn><eissn>1524-4563</eissn><coden>HPRTDN</coden><abstract>Kidney failure is the common end of hypertension and renal diseases. Several authors have suggested that vasodilatory prostaglandins participate in the hemodynamic mechanism responsible for the development of kidney failure. However, the mechanism by which prostaglandins are increased in renal disease is not clear. Recently, 2 isoforms of the enzyme responsible for prostaglandin synthesis, cyclooxygenase, have been described as cyclooxygenase-1 (COX-1), a constitutive isoform, and cyclooxygenase-2 (COX-2), an inducible isoform. In the present study, we investigated whether COX-2-dependent prostaglandins participate in the evolution of renal functional changes after renal ablation. We inhibited prostaglandin synthesis by COX-1 and COX-2 with indomethacin (3 mg/kg) and prostaglandin synthesis by COX-2 with NS-398 (3 mg/kg) and tested the effect of these inhibitors on the renal functional changes elicited by renal ablation. Renal ablation produced an increase in urinary volume, protein, and prostaglandin E2, whereas urinary sodium and potassium were not affected and urinary osmolarity decreased; treatment with indomethacin or NS-398 partially prevented the renal functional changes elicited by renal ablation. Immunoblots for COX showed an increase in the expression of COX-2 protein 2 days after renal ablation. Furthermore, COX-2 mRNA expression was increased 1 day after renal ablation. These data suggest that COX-2-dependent prostaglandins participate in the renal mechanisms associated with the development of renal functional changes after renal ablation.</abstract><cop>Philadelphia, PA</cop><cop>Hagerstown, MD</cop><pub>American Heart Association, Inc</pub><pmid>10523372</pmid><doi>10.1161/01.hyp.34.4.848</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0194-911X
ispartof Hypertension (Dallas, Tex. 1979), 1999-10, Vol.34 (4, Part 2), p.848-853
issn 0194-911X
1524-4563
language eng
recordid cdi_proquest_miscellaneous_70853739
source MEDLINE; American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Ovid Autoload
subjects Animals
Biological and medical sciences
Cyclooxygenase 1
Cyclooxygenase 2
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors - pharmacology
Cyclooxygenase Inhibitors - therapeutic use
Dinoprostone - physiology
Indomethacin - pharmacology
Indomethacin - therapeutic use
Isoenzymes - physiology
Kidney Function Tests
Male
Medical sciences
Membrane Proteins
Nephrology. Urinary tract diseases
Nephropathies. Renovascular diseases. Renal failure
Nitrobenzenes - pharmacology
Nitrobenzenes - therapeutic use
Prostaglandin-Endoperoxide Synthases - physiology
Rats
Rats, Wistar
Renal failure
Renal Insufficiency - metabolism
Renal Insufficiency - physiopathology
Renal Insufficiency - prevention & control
Sulfonamides - pharmacology
Sulfonamides - therapeutic use
title Effect of Cyclooxygenase-2 Inhibition on Renal Function After Renal Ablation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T04%3A43%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Cyclooxygenase-2%20Inhibition%20on%20Renal%20Function%20After%20Renal%20Ablation&rft.jtitle=Hypertension%20(Dallas,%20Tex.%201979)&rft.au=Sanchez,%20Pedro%20Lopez&rft.date=1999-10&rft.volume=34&rft.issue=4,%20Part%202&rft.spage=848&rft.epage=853&rft.pages=848-853&rft.issn=0194-911X&rft.eissn=1524-4563&rft.coden=HPRTDN&rft_id=info:doi/10.1161/01.hyp.34.4.848&rft_dat=%3Cproquest_cross%3E70853739%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=205291936&rft_id=info:pmid/10523372&rfr_iscdi=true